cisplatin / Generic mfg. - LARVOL DELTA

IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery. (PubMed, Future Oncol) - P3 | "The standard-of-care for muscle-invasive bladder cancer is radical surgery with neoadjuvant cisplatin-based chemotherapy. IMvigor011 (NCT04660344) is a global, double-blind, randomized phase III study assessing the efficacy of atezolizumab (anti-PD-L1) versus placebo in patients with high-risk muscle-invasive bladder cancer who are ctDNA positive post-cystectomy. The primary end point is disease-free survival in participants who are ctDNA positive within 20 weeks of cystectomy."

Circulating tumor DNA • Journal • Post-surgery • Review • Surgery • Bladder Cancer • Genito-urinary Cancer • Immune Modulation • Oncology • Solid Tumor • Urothelial Cancer

Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study. (ASCO-GU 2026) - P3 | " Pts with clinical stage T2-T4aN0M0 or T1-T4aN1M0 MIBC (confirmed by central pathology and central imaging assessment) who were eligible for cisplatin-based chemotherapy and RC + PLND were randomized 1:1 to receive either 4 cycles neoadjuvant EV 1.25 mg/kg IV on days 1 and 8 + pembro 200 mg IV on day 1 Q3W, followed by RC + PLND, and adjuvant 5 cycles EV + 13 cycles pembro (EV + pembro arm) vs 4 cycles neoadjuvant gemcitabine 1000 mg/m2 on days 1 and 8 + cisplatin 70 mg/m2 on day 1 Q3W, followed by RC + PLND (cis + gem arm). Neoadjuvant and adjuvant EV + pembro significantly improved EFS, OS, and pCR rate compared with neoadjuvant gem + cis in pts with MIBC who were eligible for cisplatin-based chemotherapy. The safety profile of EV + pembro was consistent with prior experience with the combination. These results support EV + pembro as an effective perioperative treatment option in this setting."

Clinical • Late-breaking abstract • P3 data • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

Impact of lymph node dissection extent on disease-free survival with postoperative nivolumab plus concurrent chemoradiotherapy in head and neck squamous cell carcinoma: A post-hoc analysis of the NIVOPOSTOP trial. (ASCO 2026) - P3 | "The DFS benefit of adding nivolumab to standard postoperative therapy (cisplatin-RT) was not changed by whether the LND was bilateral or unilateral and persisted in patients in whom more than 39 cervical lymph nodes were removed, on one or both sides. As such, no evidence supports reducing the extent of neck LND when immunotherapy is incorporated into the management of high risk resected HNSCC."

Retrospective data • Head and Neck Cancer • Hypopharyngeal Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Brief Report: First-line Chemoimmunotherapy and Chemotherapy Outcomes in Patients with RET Fusion-Positive Lung Cancer in LIBRETTO-431. (PubMed, J Thorac Oncol) - "In patients with advanced RET fusion-positive lung cancer treated in this global, multicenter trial, outcomes with first-line chemoimmunotherapy and chemotherapy were not significantly different in this secondary analysis. Using chemotherapy alone is a reasonable strategy for these oncogene-driven tumors. Based on the overall findings from LIBRETTO-431, selective RET inhibitors remain the preferred first-line therapy for patients with RET fusion-positive NSCLC."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1 • RET

First-Line Trastuzumab Deruxtecan (T-DXd) in Patients With Metastatic HER2 -Mutant NSCLC: DESTINY-Lung04 Primary Results (IASLC-WCLC 2026) - P3 | "Patients were randomized 1:1 to T-DXd 5.4 mg/kg IV Q3W or pembro 200 mg IV Q3W plus platinum chemo (cisplatin 75 mg/m 2 or carboplatin AUC 5 IV Q3W) and pemetrexed 500 mg/m 2 IV Q3W. Safety was generally consistent with the known profile of T-DXd. These results support T-DXd as a new first-line option for advanced/metastatic HER2 -mutant NSCLC."

Clinical • IO biomarker • Late-breaking abstract • Metastases • Inflammation • Interstitial Lung Disease • Lung Cancer • Non Small Cell Lung Cancer • Pneumonia • Pulmonary Disease • Respiratory Diseases • Solid Tumor • HER-2

Efficacy and Safety of HS-10370 Combined With Adebrelimab and Chemotherapy in First-Line Advanced KRAS G12C-Mutated NSCLC (IASLC-WCLC 2026) - P1 | "Methods : Treatment-naïve pts with locally advanced/metastatic non-squamous NSCLC and KRAS G12C mutation received HS-10370 (400 mg or 800 mg) orally once daily, adebrelimab (20 mg/kg) intravenously every 3 weeks (Q3W), and pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC 5 mg/ml/min) intravenously Q3W (4-6 cycles for platinum-based drugs), until disease progression or unacceptable toxicity. Conclusions : HS-10370 in combination with adebrelimab and platinum-based chemotherapy demonstrated a manageable safety profile and promising anti-tumor activity as 1L treatment for advanced NSCLC with KRAS G12C mutation across all PD-L1 expression levels. These findings suggest a longer survival follow-up for RP3D determination and further evaluation in a randomized phase 3 trial."

Clinical • IO biomarker • Metastases • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Neutropenia • Non Small Cell Lung Cancer • Solid Tumor • KRAS

Pathological Response and MRD Dynamics After Neoadjuvant Serplulimab Plus Chemotherapy in Stage IIB-IIIB(N2) LS-SCLC (IASLC-WCLC 2026) - P2 | "Patients received neoadjuvant therapy consisting of 4 cycles of serplulimab at 300 mg combined with etoposide and either cisplatin or carboplatin. MRD clearance after neoadjuvant therapy was associated with pCR, and surgery further facilitated MRD clearance. The early EFS data are promising; nevertheless, long-term follow-up is ongoing to further confirm the survival benefits of this strategy."

Clinical • Lung Cancer • Small Cell Lung Cancer • Solid Tumor

Serplulimab Combined With Concurrent Chemoradiotherapy Followed by Serplulimabtherapy for LS-SCLC: A Phase 2 Trial (IASLC-WCLC 2026) - P2 | "Eligible patients received 4 cycles of serplulimab administered concurrently with etoposide plus cisplatin/carboplatin and thoracic radiotherapy, followed by serplulimab maintenance therapy until disease progression or for a maximum of 1 year. Conclusions : In this ongoing phase 2 trial, serplulimab combined with cCRT followed by serplulimab maintenance therapy has demonstrated promising antitumor activity and a favorable early survival trend, with acceptable tolerability and manageable safety profile. Longer follow-up is warranted to validate the survival benefits of this regimen."

P2 data • Lung Cancer • Pneumonia • Small Cell Lung Cancer • Solid Tumor

Safety and efficacy of cisplatin and nab-paclitaxel pressurised intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal carcinomatosis: Nab-PIPAC phase 1b study. (PubMed, EBioMedicine) - "The combination of nab-paclitaxel and cisplatin administered by PIPAC was safe and well tolerated in patients with peritoneal carcinomatosis. Further investigation of this combination is warranted."

Journal • P1 data • Gastric Cancer • Gastrointestinal Cancer • Oncology • Ovarian Cancer • Pain • Pancreatic Cancer • Peritoneal Cancer • Solid Tumor

Induction Paclitaxel-Cisplatin-Capecitabine for Nasopharyngeal Carcinoma. (PubMed, NEJM Evid) - P3 | "Among patients with high-risk LA-NPC, TPC induction chemotherapy was associated with higher 5-year FFS than PF. (Funded by National Natural Science Foundation of China and State Key Laboratory of Respiratory Disease; ClinicalTrials.gov number, NCT02940925.)."

Clinical • Journal • Epstein-Barr Virus Infections • Nasopharyngeal Carcinoma • Oncology • Respiratory Diseases • Solid Tumor

Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and gallbladder carcinoma (ACTICCA-1 trial) (ESMO 2026) - No abstract available

Clinical • Late-breaking abstract • Biliary Cancer • Cholangiocarcinoma • Gallbladder Cancer • Oncology • Solid Tumor

The Inhibition of Histone Lysine Demethylases Affects Head and Neck Cancer Cell Growth and Response to Cisplatin. (PubMed, Genes (Basel)) - "In addition, the chemicals significantly reduced the expression of pluripotency markers, especially SOX2. In conclusion, KDM4-6 inhibitors significantly affected HNSCC cell growth, and exerted the potential for epigenetic priming in combination with cisplatin."

IO biomarker • Journal • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • KDM5D • KDM6A • SOX2

Anticancer Effects of Fluphenazine Alone and in Combination with Cisplatin in Gastric Cancer Cells and a Mouse Xenograft Model. (PubMed, Pharmaceuticals (Basel)) - "In the mouse xenograft model, the tumor volumes were 1233.65, 1115.75, 768.88, and 309.44 mm3 in the control, FPZ, DDP, and combination groups, respectively. These findings support the potential of FPZ as a repurposed anticancer agent for gastric cancer, particularly in combination with DDP."

Journal • Preclinical • CNS Disorders • Gastric Cancer • Oncology • Solid Tumor • CXCL8 • DRD2 • IL6

Echinacoside Alleviates Cisplatin-Induced Acute Kidney Injury by Regulating Bap1 to Inhibit Ferroptosis. (PubMed, Biomedicines) - " ECH mitigates cisplatin-triggered AKI, which is associated with Bap1 downregulation, Slc7a11/GPX4 axis restoration, and ferroptosis suppression. The ECH-Bap1-ferroptosis regulatory relationship offers a candidate therapeutic target and natural agent for the preventive treatment of cisplatin-related nephrotoxicity."

Journal • Acute Kidney Injury • Inflammation • Nephrology • Renal Disease • BAP1 • GPX4 • SLC7A11

Cisplatin combined with high-intensity focused ultrasound inhibits endometrial cancer progression by inducing pyroptosis. (PubMed, Int J Hyperthermia) - "In vivo, cisplatin combined with HIFU markedly restrained xenograft tumor growth and promoted tumor pyroptosis, whereas 740 Y-P pretreatment counteracted these effects. Cisplatin combined with HIFU suppresses Type I endometrial cancer progression by inhibiting PI3K/AKT signaling and promoting pyroptosis, supporting its potential as a novel combination therapeutic strategy."

Journal • Endometrial Cancer • Oncology • Solid Tumor

Clinical and Public Health Lessons from a Point-Source Polymicrobial Foodborne Outbreak: Implications for Vaccination of Vulnerable Populations. (PubMed, Vaccines (Basel)) - "This outbreak demonstrates how identical environmental exposure may result in markedly different clinical outcomes according to host immune status. While rigorous food safety measures remain essential, these findings may help develop hypotheses regarding populations that could be considered in future studies of enteric vaccination strategies. Outbreak investigations may therefore contribute not only to source identification and outbreak control but also to informing future vaccination strategies for vulnerable populations."

Journal • Cervical Cancer • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Oncology • Solid Tumor

Treatment Outcomes and Toxicity of Cisplatin-Etoposide-Based Regimens and Carboplatin-Paclitaxel as Adjuvant Chemotherapy for Ovarian Adult Granulosa Cell Tumors: A Multicenter Retrospective Cohort Study. (PubMed, Cancers (Basel)) - "This study compared disease-free survival (DFS), treatment delivery, and toxicity between bleomycin-etoposide-cisplatin/etoposide-cisplatin (BEP/EP) and carboplatin-paclitaxel (CP) in the postoperative adjuvant setting. No statistically significant difference in DFS was detected between BEP/EP and CP, while distinct toxicity patterns were observed. Given the retrospective design, limited sample size, and potential for treatment-selection bias and residual confounding, these findings should be considered exploratory and should not be interpreted as evidence of equivalent efficacy between the regimens."

Journal • Retrospective data • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Pain

Prediction of Acute Kidney Injury in Oncology: From Clinical Risk Scores to AI-Enabled Precision Onco-Nephrology. (PubMed, Cancers (Basel)) - " Prediction evidence is most developed in hospitalized cancer populations, cisplatin exposure, contrast-enhanced computed tomography, immune checkpoint inhibitor therapy, and selected oncologic surgical procedures...Clinical progress will require standardized outcomes, treatment-aware longitudinal data, rigorous external validation, and prediction tools linked to evidence-based response pathways. These advances may ultimately enable precision onco-nephrology by supporting proactive kidney protection while preserving optimal cancer treatment."

Journal • Review • Acute Kidney Injury • Bone Marrow Transplantation • Nephrology • Oncology • Renal Disease • Transplantation

Complete pathological response after neoadjuvant chemoimmunotherapy in PD-L1-negative unresectable primary hepatic small cell carcinoma: a case report and tumor microenvironment analysis. (PubMed, Front Immunol) - "She received neoadjuvant therapy with cisplatin/carboplatin, etoposide, and serplulimab; after the first cycle, cisplatin was switched to carboplatin due to renal impairment. The response may be mediated by a chemotherapy-synergized, PD-1 inhibitor-driven immune activation within a receptive tumor microenvironment, particularly the stromal compartment. The presence of an immune-rich stroma may serve as a critical determinant for immunotherapy efficacy, highlighting the limitations of relying solely on tumor cell PD-L1 expression as a biomarker in this rare malignancy."

Biomarker • IO biomarker • Journal • Endocrine Cancer • Neuroendocrine Carcinoma • Oncology • Renal Disease • Solid Tumor • CD38 • CD8 • PD-L1

Multiple Options, One Objective: Clearer Decisions in Resectable Non-Small Cell Lung Cancer. (PubMed, Cancers (Basel)) - "Treatment of resectable NSCLC should be individualized based on stage, nodal status, PD-L1 expression, molecular alterations and pCR. Upfront surgery with adjuvant therapy is appropriate for lower-stage disease (IB-IIA), while perioperative chemoimmunotherapy offers maximal benefit in stage II-III, especially N2-positive patients. Biomarker-driven strategies will continue to refine patient selection to stop or continue postoperative treatment."

IO biomarker • Journal • Review • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR

Ellagic Acid and Metformin: In Vitro Synergy and Enhanced Cisplatin Efficacy In Vivo in Resistant Breast Cancer. (PubMed, Nutrients) - " Thecombination of metformin and ellagic acid shows promise as a potential treatment for cisplatin-resistant breast cancer. Further research is needed to elucidate the precise anticancer mechanisms underlying this combination."

Journal • Preclinical • Breast Cancer • Oncology • Solid Tumor • CASP3

Combining Selective Internal Radiation Therapy (SIRT) and Systemic Therapy in Intrahepatic Cholangiocarcinoma. (PubMed, Cancers (Basel)) - "To date, no completed randomized trial exists on combined locoregional SIRT and systemic therapy in patients with iCCA. SIRT should be considered a multimodal personalized therapeutic treatment option in patients with upfront unresecatable liver predominant disease."

Journal • Biliary Cancer • Cholangiocarcinoma • Liver Cancer • Oncology • Solid Tumor • Transplantation

NRF2/SLC7A11/GPX4 Antioxidant Axis Suppression by Camel Milk Whey Protein Sensitizes MCF-7 Breast Cancer Cells to Cisplatin. (PubMed, Int J Mol Sci) - "In silico evaluations further reinforced the clinical relevance of this axis, revealing that elevated NRF2 and SLC7A11 expression correlates with poor relapse-free survival and recurrent genomic alterations across breast cancer cohorts. Ultimately, these results demonstrate that CMP disrupts the NRF2/SLC7A11/GPX4 antioxidant axis in cancer cells, offering a promising, selective strategy to enhance cisplatin sensitivity while safeguarding healthy tissues."

Journal • Breast Cancer • Oncology • Solid Tumor • GPX4 • SLC7A11

Association of the Preoperative CALLY Index with Acute Kidney Injury After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Comparison with Other Inflammatory and Immune-Nutritional Indices. (PubMed, J Clin Med) - "All received intraoperative cisplatin and mitomycin C. AKI was defined according to Kidney Disease: Improving Global Outcomes serum creatinine criteria. In this selected retrospective cohort of patients without established chronic kidney disease, a lower preoperative CALLY index was associated with postoperative AKI and showed moderate discrimination as an individual marker. The data-derived threshold should be considered exploratory and requires independent validation before clinical application."

Journal • Acute Kidney Injury • Chronic Kidney Disease • Immunology • Inflammation • Nephrology • Renal Disease • Systemic Inflammatory Response Syndrome • CRP

STING-IL-6 signaling in sensory neurons drives cisplatin-induced neuropathic pain. (PubMed, Brain Behav Immun) - "Pharmacological inhibition of STING reduced CINP development and IL-6 upregulation and prevented epidermal sensory fiber loss. Together, these findings identify a previously unrecognized pronociceptive role for STING signaling in nociceptors during CINP and support peripheral STING inhibition as a therapeutic strategy."

IO biomarker • Journal • Metabolic Disorders • Neuralgia • Pain • BAX • IL6 • STING